April 20, 2018 Conference
Traditional Diode laser transcleral cyclophotocoagulation (TSCPC) is a commonly used procedure for lowering IOP in patients with difficult to treat glaucoma. It works by damaging the ciliary body, which decreases aqueous production. Typical patients have had previous glaucoma surgeries and have limited visual potential. Although effective, the extensive tissue destruction can lead to complications such as prolonged inflammation, hypotony, and vision loss. The development of Micropulse Diode CPC is an attempt to harness the IOP lowering benefits of the traditional procedure while reducing risks and potentially broadening the clinical applications. I will review the current experience with Micropulse CPC, including results, patient selection, and evolving techniques.